Beamtree Holding Limited announced a new agreement with Abbott ("Abbott"), a leading global healthcare company, to distribute Beamtree's RippleDown® products. The new agreement marks a great step forward and a renewed joint approach to advancing automation and value through Beamtree's core Diagnostics product, RippleDown®. The key terms of the new distribution agreement are as follows: The term of the agreement is 3 years with an option to extend for years 4 and 5. For any sales during the contractual period Beamtree will commit to providing the RippleDown® product for the duration of the end customer contract.

Abbott retains exclusive distribution rights, except for a single existing distribution agreement. Abbott will distribute RippleDown® branded as AlinIQ Clinical Decision Support, Powered by RippleDown® in pathology and radiology. Abbott to pay an annual product fee for smaller single laboratory clients and revenue share for larger customers.

In the context of Beamtree's current company forecast, Beamtree expects the agreement to be a material contribution to its total revenue.